CYCLERION THERAPEUTICS, INC. Operating Expenses
CYCLERION THERAPEUTICS, INC. (CYCN) reported Operating Expenses of $1.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- CYCLERION THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $1.77M, a 0.34% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $3.21M, a 108.65% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $1.86M, a 42.87% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $1.88M, a 42.28% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. operating expenses for fiscal 2023 was $12.95M, a 31.25% decline from fiscal 2022.
- CYCLERION THERAPEUTICS, INC. operating expenses for fiscal 2022 was $18.84M, a 68.15% decline from fiscal 2021.
- CYCLERION THERAPEUTICS, INC. operating expenses for fiscal 2021 was $59.14M, a 29.23% decline from fiscal 2020.
- CYCLERION THERAPEUTICS, INC. operating expenses for fiscal 2020 was $83.56M, a 35.50% decline from fiscal 2019.
| Period end | Operating Expenses | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.77M 10-Q · filed 2026-08-04 | $4.98M 10-Q · filed 2026-08-04 | $6.84M derived: sum of 3 quarters · filed 2026-08-04 | $8.72M derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2026-03-31 | $3.21M S-4/A · filed 2026-07-22 | $5.07M derived: sum of 2 quarters · filed 2026-07-22 | $6.95M derived: sum of 3 quarters · filed 2026-07-22 | $8.72M derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-12-31 | $1.86M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | $3.74M derived: sum of 2 quarters · filed 2026-07-22 | $5.51M derived: sum of 3 quarters · filed 2026-08-04 | $7.05M S-4/A · filed 2026-07-22 | |||||
| 2025-09-30 | $1.88M 10-Q · filed 2025-11-12 | $3.65M derived: sum of 2 quarters · filed 2026-08-04 | $5.18M 10-Q · filed 2025-11-12 | $6.49M derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-06-30 | $1.76M 10-Q · filed 2026-08-04 | $3.30M 10-Q · filed 2026-08-04 | $4.61M derived: sum of 3 quarters · filed 2026-08-04 | $5.93M derived: sum of 4 quarters · filed 2026-08-04 | |||||
| 2025-03-31 | $1.54M S-4/A · filed 2026-07-22 | $2.84M derived: sum of 2 quarters · filed 2026-07-22 | $4.16M derived: sum of 3 quarters · filed 2026-07-22 | $5.55M derived: sum of 4 quarters · filed 2026-07-22 | |||||
| 2024-12-31 | $1.30M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | $2.63M derived: sum of 2 quarters · filed 2026-07-22 | $4.01M derived: sum of 3 quarters · filed 2026-07-22 | $5.63M S-4/A · filed 2026-07-22 | |||||
| 2024-09-30 | $1.32M 10-Q · filed 2025-11-12 | $2.71M derived: sum of 2 quarters · filed 2025-11-12 | $4.32M 10-Q · filed 2025-11-12 | $6.12M derived: sum of 4 quarters · filed 2025-11-12 | |||||
| 2024-06-30 | $1.38M 10-Q · filed 2025-08-05 | $3.00M 10-Q · filed 2025-08-05 | $4.80M derived: sum of 3 quarters · filed 2025-11-12 | $10.81M derived: sum of 4 quarters · filed 2025-11-12 | |||||
| 2024-03-31 | $1.62M 10-Q · filed 2025-05-06 | $3.41M derived: sum of 2 quarters · filed 2025-11-12 | $9.43M derived: sum of 3 quarters · filed 2025-11-12 | $11.29M derived: sum of 4 quarters · filed 2025-11-12 | |||||
| 2023-12-31 | $1.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | $7.81M derived: sum of 2 quarters · filed 2025-11-12 | $9.68M derived: sum of 3 quarters · filed 2025-11-12 | $12.95M 10-K/A · filed 2025-11-12 | |||||
| 2023-09-30 | $6.01M 10-Q · filed 2024-11-14 | $7.88M derived: sum of 2 quarters · filed 2024-11-14 | $11.16M 10-Q · filed 2024-11-14 | $15.61M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-07-28 | $2.40M 10-Q · filed 2026-08-04 | ||||||||
| 2023-06-30 | $1.86M 10-Q · filed 2024-08-07 | $4.24M 10-Q · filed 2023-07-28 | $5.14M 10-Q · filed 2024-08-07 | $11.29M 10-Q · filed 2023-07-28 | $9.60M derived: sum of 3 quarters · filed 2024-08-07 | $14.11M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | $3.27M 10-Q · filed 2024-05-07 | $7.04M 10-Q · filed 2023-05-12 | $7.73M derived: sum of 2 quarters · filed 2024-05-07 | $12.25M derived: sum of 3 quarters · filed 2024-05-07 | $25.99M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $8.97M derived: sum of 2 quarters · filed 2024-03-05 | $22.71M derived: sum of 3 quarters · filed 2024-03-05 | $18.84M 10-K · filed 2024-03-05 | $46.00M 10-K · filed 2023-03-22 | ||||
| 2022-09-30 | $4.52M 10-Q · filed 2023-11-13 | $10.61M 10-Q · filed 2022-11-03 | $18.26M derived: sum of 2 quarters · filed 2023-11-13 | $14.38M 10-Q · filed 2023-11-13 | $38.04M 10-Q · filed 2022-11-03 | $46.82M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $13.74M 10-Q · filed 2023-07-28 | $27.43M 10-Q · filed 2023-07-28 | $42.30M derived: sum of 3 quarters · filed 2023-07-28 | $53.94M derived: sum of 4 quarters · filed 2023-07-28 | |||||
| 2022-03-31 | $13.70M 10-Q · filed 2023-05-12 | $28.57M derived: sum of 2 quarters · filed 2023-05-12 | $40.20M derived: sum of 3 quarters · filed 2023-05-12 | $59.38M derived: sum of 4 quarters · filed 2023-05-12 | |||||
| 2021-12-31 | $14.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $26.50M derived: sum of 2 quarters · filed 2023-03-22 | $45.68M derived: sum of 3 quarters · filed 2023-03-22 | $59.14M 10-K · filed 2023-03-22 | |||||
| 2021-09-30 | $11.63M 10-Q · filed 2022-11-03 | $30.81M derived: sum of 2 quarters · filed 2022-11-03 | $44.27M 10-Q · filed 2022-11-03 | $63.62M derived: sum of 4 quarters · filed 2022-11-03 | |||||
| 2021-06-30 | $19.18M 10-Q · filed 2022-08-09 | $32.63M 10-Q · filed 2022-08-09 | $51.99M derived: sum of 3 quarters · filed 2022-08-09 | $74.17M derived: sum of 4 quarters · filed 2022-08-09 | |||||
| 2021-03-31 | $13.46M 10-Q · filed 2022-05-04 | $32.81M derived: sum of 2 quarters · filed 2022-05-04 | $54.99M derived: sum of 3 quarters · filed 2022-05-04 | $75.42M derived: sum of 4 quarters · filed 2022-05-04 | |||||
| 2020-12-31 | $19.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $41.54M derived: sum of 2 quarters · filed 2022-02-24 | $61.96M derived: sum of 3 quarters · filed 2022-02-24 | $83.56M 10-K · filed 2022-02-24 | |||||
| 2020-09-30 | $22.18M 10-Q · filed 2021-11-09 | $42.60M derived: sum of 2 quarters · filed 2021-11-09 | $64.20M 10-Q · filed 2021-11-09 | $92.27M derived: sum of 4 quarters · filed 2021-11-09 | |||||
| 2020-06-30 | $20.42M 10-Q · filed 2021-07-29 | $42.02M 10-Q · filed 2021-07-29 | $70.09M derived: sum of 3 quarters · filed 2021-07-29 | $99.50M derived: sum of 4 quarters · filed 2021-07-29 | |||||
| 2020-03-31 | $21.60M 10-Q · filed 2021-04-30 | $49.67M derived: sum of 2 quarters · filed 2021-04-30 | $79.08M derived: sum of 3 quarters · filed 2021-04-30 | $113.77M derived: sum of 4 quarters · filed 2021-04-30 | |||||
| 2019-12-31 | $28.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $57.48M derived: sum of 2 quarters · filed 2021-02-25 | $92.16M derived: sum of 3 quarters · filed 2021-02-25 | $129.54M 10-K · filed 2021-02-25 | |||||
| 2019-09-30 | $29.41M 10-Q · filed 2020-11-05 | $64.10M derived: sum of 2 quarters · filed 2020-11-05 | $101.48M 10-Q · filed 2020-11-05 | $132.38M derived: sum of 4 quarters · filed 2020-11-05 | |||||
| 2019-06-30 | $34.68M 10-Q · filed 2020-08-03 | $72.06M 10-Q · filed 2020-08-03 | $102.97M derived: sum of 3 quarters · filed 2020-08-03 | $132.25M derived: sum of 4 quarters · filed 2020-08-03 | |||||
| 2019-03-31 | $37.38M 10-Q · filed 2020-05-04 | $68.28M derived: sum of 2 quarters · filed 2020-05-04 | $97.57M derived: sum of 3 quarters · filed 2020-05-04 | $127.35M derived: sum of 4 quarters · filed 2020-05-04 | |||||
| 2018-12-31 | $30.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $60.19M derived: sum of 2 quarters · filed 2020-03-12 | $89.97M derived: sum of 3 quarters · filed 2020-03-12 | $115.25M 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | $29.29M 10-Q · filed 2019-11-12 | $59.07M derived: sum of 2 quarters · filed 2019-11-12 | $84.35M 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | $29.78M 10-Q · filed 2019-08-12 | $55.06M 10-Q · filed 2019-08-12 | |||||||
| 2018-03-31 | $25.28M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |